Primary outcome | Slope of eGFR over 24 months |
---|---|
Secondary outcomes | Graft and patient survival at 24 months |
Measured GFR (Cr-51-EDTA method) at 24 months | |
DSA at 6, 12, 18, and 24 months | |
Mean fluorescence intensity levels | |
Number of human leukocyte antigen specificities | |
Urinary protein excretion (protein/creatinine ratio) at 6, 12, 18, and 24 months | |
Occurrence of biopsy-proven acute rejection necessitating rejection treatment | |
Acute AMR score in a protocol biopsy performed at 24 months | |
Chronic AMR score in a protocol biopsy performed 24 months |